Search

Your search keyword '"Cartabellotta F"' showing total 98 results
Start Over Author "Cartabellotta F"
98 results on '"Cartabellotta F"'

1. T.07.7: CHARACTERISTICS AND MANAGEMENT OF HEPATOCELLULAR CARCINOMA (HCC) IN SICILY: FIRST RESULTS OF THE HCC SICILY MULTIDISCIPLINARY NETWORK

Author

Celsa, C., primary, Cabibbo, G., additional, Ciccia, R., additional, Di Maria, G., additional, Pagano, D., additional, Miraglia, R., additional, Maruzzelli, L., additional, Bavetta, M.G., additional, Barcellona, M.R., additional, Cocuzza, C., additional, Tavarelli, M., additional, Filomia, R., additional, Pitrone, C., additional, Malizia, G., additional, Bertino, G., additional, Salomone, F., additional, Distefano, M., additional, Mitra, M., additional, Cartabellotta, F., additional, Giannitrapani, L., additional, Giuffrida, D., additional, Spada, M., additional, Alaimo, G., additional, Sambataro, D., additional, Sportato, G., additional, Grassini, M.V., additional, Cannella, R., additional, Antonucci, M., additional, D'Amato, F., additional, Capodicasa, L., additional, Grova, A., additional, Rao, S., additional, Salvato, M., additional, Cusimano, G., additional, Gaudioso, V., additional, Sparacino, A., additional, Mercurio, F., additional, Rizzo, G.E.M., additional, Picciotto, V., additional, Montenegro, R., additional, Arena, S., additional, Saitta, C., additional, Russello, M., additional, Fusco, G., additional, Di Marco, V., additional, Gruttadauria, S., additional, and Cammà, C., additional

Published
2024
Full Text
View/download PDF

3. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

Author

Craxì, A., Di Marco, V., Cammà, C., Calvaruso, V., Petta, S., Cabbibbo, G., Colletti, P., Mazzola, G., Cascio, A., Montalto, G., Licata, A., Giannitrapani, L., Prestileo, T., Di Lorenzo, F., Sanfilippo, A., Ficalora, A., Madonia, S., Tinè, F., Malizia, G., Latteri, F., Maida, M., Cartabellotta, F., Vassallo, R., Cacciola, I., Caccamo, G., Maimone, S., Saitta, C., Squadrito, G., Raimondo, G., Mondello, L., Smedile, A., D’Andrea, S., Bertino, G., Ardiri, A.L., Frazzetto, E., Rigano, G., Montineri, A., Larocca, L.N., Cacopardo, B., Benanti, F., Russello, M., Benigno, R., Bellia, A., Iacobello, C., Davì, A., Di Rosolini, M.A., Digiacomo, A., Fuduli, G., Scifo, G., Distefano, M., Portelli, V., Savalli, F., Scalici, I., Gioia, G., Magro, A., Alaimo, G., Alinovi, M.R., Salvo, A., Averna, A., Lomonaco, F., Guarneri, L., Maffeo, F., Falzone, E., Pulvirenti, F., Calvaruso, Vincenza, Cabibbo, Giuseppe, Cacciola, Irene, Petta, Salvatore, Madonia, Salvatore, Bellia, Alessandro, Tinè, Fabio, Distefano, Marco, Licata, Anna, Giannitrapani, Lydia, Prestileo, Tullio, Mazzola, Giovanni, Di Rosolini, Maria Antonietta, Larocca, Licia, Bertino, Gaetano, Digiacomo, Antonio, Benanti, Francesco, Guarneri, Luigi, Averna, Alfonso, Iacobello, Carmelo, Magro, Antonio, Scalisi, Ignazio, Cartabellotta, Fabio, Savalli, Francesca, Barbara, Marco, Davì, Antonio, Russello, Maurizio, Scifo, Gaetano, Squadrito, Giovanni, Cammà, Calogero, Raimondo, Giovanni, Craxì, Antonio, and Di Marco, Vito

Published
2018
Full Text
View/download PDF

5. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study

Author

Cabibbo, G., Petta, S., Calvaruso, V., Cacciola, I., Cannavò, M. R., Madonia, S., Distefano, M., Larocca, L., Prestileo, T., Tinè, F., Bertino, G., Giannitrapani, L., Benanti, F., Licata, A., Scalisi, I., Mazzola, G., Cartabellotta, F., Alessi, N., Barbàra, M., Russello, M., Scifo, G., Squadrito, G., Raimondo, G., Craxì, A., Di Marco, V., Cammà, C., Craxì, A., Di Marco, V., Cammà, C., Calvaruso, V., Petta, S., Colletti, P., Mazzola, G., Licata, A., Giannitrapani, L., Corrao, S., Prestileo, T., Di Lorenzo, F., Fecarotta, R., Sanfilippo, P., Madonia, S., Tinè, F., Malizia, G., Latteri, F., Maida, M., Cartabellotta, F., Vassallo, R., Cacciola, I., Caccamo, G., Maimone, S., Saitta, C., Squadrito, G., Raimondo, G., Mondello, L., Smedile, A., Bertino, G., Ardiri, A.L., Montineri, A., Larocca, L. N., Cacopardo, B., Benanti, F., Russello, M., Benigno, R., Cannavò, M. R., Bellia, A., Iacobello, C., Davì, A., Di Rosolini, M. A., Digiacomo, A., Fuduli, G., Scifo, G., Distefano, M., Portelli, V., Savalli, F., Scalici, I., Gioia, G., Magro, A., Alaimo, G., Salvo, A., Averna, A., Lomonaco, F., Quattrocchi, U., Guarneri, L., and Maffeo, F.

Published
2017
Full Text
View/download PDF

6. Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort

Author

Salomone, F., primary, Cacciola, I., additional, Petta, S., additional, Calvaruso, V., additional, Micek, A., additional, Madonia, S., additional, Grova, M., additional, Distefano, M., additional, Cannavò, M., additional, Di Rosolini, M.A., additional, Digiacomo, A., additional, Di Lorenzo, F., additional, Bertino, G., additional, Licata, A., additional, Latteri, F., additional, Benanti, F., additional, Averna, A., additional, Guarneri, L., additional, Scalisi, I., additional, Iacobello, C., additional, Montineri, A., additional, Colletti, P., additional, Cartabellotta, F., additional, Davì, A., additional, Russello, M., additional, Scifo, G., additional, Squadrito, G., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2022
Full Text
View/download PDF

7. Gamma Glutamyl Transferase as a marker of risk of progression to cirrhosis in patients with Primary Biliary Cholangitis

Author

Calvaruso, V., primary, Saitta, C., additional, Russello, M., additional, Fichera, A., additional, Bertino, G., additional, Bueti, FM., additional, Bronte, F., additional, Di Stefano, M., additional, Giacchetto, M., additional, Salomone, F., additional, Madonia, S., additional, Cadamuro, L., additional, Franzè, MS., additional, Licata, A., additional, Alaimo, G., additional, Pitrone, C., additional, Minissale, M., additional, Sapienza, M., additional, Cannavò, M.R., additional, Cartabellotta, F., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2022
Full Text
View/download PDF

8. Real life experiences in HCV management in 2018

Author

Vigano, M, Andreoni, M, Perno, C, Craxi, A, Aghemo, A, Alberti, A, Andreone, P, Babudieri, S, Bonora, S, Brunetto, M, Bruno, R, Bruno, S, Calvaruso, V, Caporaso, N, Cartabellotta, F, Ceccherini-Silberstein, F, Cento, V, Ciancio, A, Colombatto, P, Coppola, N, Di Marco, V, Di Perri, G, Fagiuoli, S, Gaeta, G, Gasbarrini, A, Lampertico, P, Pellicelli, A, Prestileo, T, Puoti, M, Raimondo, G, Rizzardini, G, Taliani, G, Zignego, A, Vigano M., Andreoni M., Perno C. F., Craxi A., Aghemo A., Alberti A., Andreone P., Babudieri S., Bonora S., Brunetto M. R., Bruno R., Bruno S., Calvaruso V., Caporaso N., Cartabellotta F., Ceccherini-Silberstein F., Cento V., Ciancio A., Colombatto P., Coppola N., Di Marco V., Di Perri G., Fagiuoli S., Gaeta G. B., Gasbarrini A., Lampertico P., Pellicelli A., Prestileo T., Puoti M., Raimondo G., Rizzardini G., Taliani G., Zignego A. L., Vigano, M, Andreoni, M, Perno, C, Craxi, A, Aghemo, A, Alberti, A, Andreone, P, Babudieri, S, Bonora, S, Brunetto, M, Bruno, R, Bruno, S, Calvaruso, V, Caporaso, N, Cartabellotta, F, Ceccherini-Silberstein, F, Cento, V, Ciancio, A, Colombatto, P, Coppola, N, Di Marco, V, Di Perri, G, Fagiuoli, S, Gaeta, G, Gasbarrini, A, Lampertico, P, Pellicelli, A, Prestileo, T, Puoti, M, Raimondo, G, Rizzardini, G, Taliani, G, Zignego, A, Vigano M., Andreoni M., Perno C. F., Craxi A., Aghemo A., Alberti A., Andreone P., Babudieri S., Bonora S., Brunetto M. R., Bruno R., Bruno S., Calvaruso V., Caporaso N., Cartabellotta F., Ceccherini-Silberstein F., Cento V., Ciancio A., Colombatto P., Coppola N., Di Marco V., Di Perri G., Fagiuoli S., Gaeta G. B., Gasbarrini A., Lampertico P., Pellicelli A., Prestileo T., Puoti M., Raimondo G., Rizzardini G., Taliani G., and Zignego A. L.

Abstract

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this meeting and the final statements are reported in this paper. Expert commentary: All the advances on HCV cure may have a real clinical impact not only in individual patients but also at the social health level if they are applied to all infected patients, independently from the stage of liver disease. Further improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.

Published
2019

9. Management of Patients with Gastric or Gastroesophageal Junction Cancer: From Theory to Integrated Clinical Pathways Implementation in the Real World.

Author

Guggino, R., Borsellino, N., Spada, M., Verderame, F., Mezzatesta, P., Marchesa, P., Firenze, A., Cartabellotta, F., Fazio, I., Pergolizzi, S., Callari, C., and Gebbia, V.

Subjects
ESOPHAGOGASTRIC junction cancer, STOMACH cancer, MEDICAL personnel, HEALTH outcome assessment, ONCOLOGY
Abstract

Introduction. Best care of esophagogastric junction and gastric cancer ((EGC) requires a complex, timely interaction between members of a multi-disciplinary team (MDT). An integrated clinical pathway (ICP) is necessary to achieve this goal as well as the implementation of its use in daily practice. The objective of this study was to elaborate on an integrated clinical pathway for the multi-disciplinary management of ECG. Authors also put in act an implementation program to improve adherence to guidelines thought an ICP. Method. This prospective work carried out by a multi-institutional MDT in Italy identified expert panel extracted relevant recommendations and/or statements from published papers and guidelines obtaining a set of crucial interventions employed the Estimate-Talk-Estimate method. A flow-chart diagram was elaborated to elicit the process at a glance. The primary outcome measure was the elaboration of an ICP with a high consensus rate also reported as a snapshot diagram and its implementation in daily clinical practice. An accredited certification body agency validated results, and an implementation process was started in several hospitals known to treat ECG. Results. A methodologist aggregated a multi-disciplinary panel of experts from different institutions. The panel elaborated a flow-chart diagram with crucial intervention highlight and connecting lines, as well as outcome measures. An accredited certification body agency validated the entire process, representing the basis for empowerment and implementation among patients and oncological professionals in various hospitals. Conclusion. The multi-disciplinary and multi-institutional expert panel successfully elaborated on a validated ICP for all stages ECG. An in-hospital implementation program has been programmed. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

12. Current epidemiology of HCV in Sicily: the RESIST-HCV model

Author

Di Marco, V., primary, Cartabellotta, F., additional, Mazzucco, W., additional, Calvaruso, V., additional, Petta, S., additional, Mazzola, S., additional, Cusimano, R., additional, Amodio, R., additional, Scifo, G., additional, Russello, M., additional, Cacopardo, B., additional, Squadrito, G., additional, Raimondo, G., additional, Pollicino, T., additional, Ceccherini-Silbertein, F., additional, Vitale, F., additional, Cammà, C., additional, and Craxì, A., additional

Published
2019
Full Text
View/download PDF

13. Second-generation DAAs for HCV: real-life efficacy in the RESIST-HCV cohort

Author

Cacciola, I., primary, Petta, S., additional, Calvaruso, V., additional, Cartabellotta, F., additional, Distefano, M., additional, Scifo, G., additional, Di Lorenzo, F., additional, Sanfilippo, A., additional, Di Rosolini, M.A., additional, Davì, A., additional, Benanti, F., additional, Cacopardo, B., additional, Licata, A., additional, Giannitrapani, L., additional, Cannavò, M.R., additional, Russello, M., additional, Madonia, S., additional, Bavetta, M.G., additional, Digiacomo, A., additional, Averna, A., additional, Alaimo, G., additional, Larocca, L., additional, Bertino, G., additional, Bronte, F., additional, Guarneri, L., additional, Scalisi, I., additional, Iacobello, C., additional, Colletti, P., additional, Portelli, V., additional, Pollicino, T., additional, Ceccherini-Silberstein, F., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2019
Full Text
View/download PDF

14. PC.01.10 LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT

Author

Magro, B., primary, Calvaruso, V., additional, Petta, S., additional, Cacciola, I., additional, Cabibbo, G., additional, Cartabellotta, F., additional, Di Rosolini, A., additional, Davì, A., additional, Cannavò, M., additional, Russello, M., additional, Di Stefano, M., additional, Scifo, G., additional, Di Lorenzo, F., additional, Prestileo, T., additional, Rocca, L. La, additional, Montineri, A., additional, Fuduli, G., additional, Digiacomo, A., additional, Cannizzaro, M., additional, Madonia, S., additional, Licata, A., additional, Malizia, G., additional, Alaimo, G., additional, Bertino, G., additional, Cacopardo, B., additional, Iacobello, C., additional, Averna, A., additional, Guarneri, L., additional, Scalisi, I., additional, Mazzola, G., additional, Mondello, L., additional, Portelli, V., additional, Squadrito, G., additional, Cammà, C., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2019
Full Text
View/download PDF

15. OC.07.1 DIRECT ACTING ANTIVIRALS AFTER SUCCESSFUL TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA IMPROVE SURVIVAL AND REDUCE HEPATIC DECOMPENSATION IN HCV-CIRRHOTIC PATIENTS

Author

Celsa, C., primary, Cabibbo, G., additional, Calvaruso, V., additional, Petta, S., additional, Cacciola, I., additional, Cannavò, M.R., additional, Madonia, S., additional, Rossi, M., additional, Magro, B., additional, Rini, F., additional, Distefano, M., additional, Larocca, L., additional, Prestileo, T., additional, Malizia, G., additional, Bertino, G., additional, Benanti, F., additional, Licata, A., additional, Scalisi, I., additional, Mazzola, G., additional, Di Rosolini, M.A., additional, Alaimo, G., additional, Averna, A., additional, Cartabellotta, F., additional, Alessi, N., additional, Guastella, S., additional, Russello, M., additional, Scifo, G., additional, Squadrito, G., additional, Raimondo, G., additional, Craxì, A., additional, Di Marco, V., additional, and Cammà, C., additional

Published
2019
Full Text
View/download PDF

16. Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy

Author

Pasulo, L., primary, Gambato, M., additional, Spinetti, A., additional, D’Ambrosio, R., additional, Puoti, M., additional, Ciancio, A., additional, Di Marco, V., additional, Calvaruso, V., additional, Colombatto, P., additional, Brunetto, M., additional, Schiavini, M., additional, Fabris, P., additional, Sacchi, P., additional, Gulminetti, R., additional, Carolo, G., additional, Scotton, P., additional, Pozzan, C., additional, Vinci, M., additional, Viganò, M., additional, Lombardi, A., additional, Bello, S. Lo, additional, Zuin, M., additional, Aghemo, A., additional, Rumi, M.G., additional, Carrara, M., additional, Manfrin, V., additional, Uberti-Foppa, C., additional, Panese, S., additional, Paon, V., additional, Pan, A., additional, Spinelli, O., additional, D’Arminio Monforte, A., additional, Colli, A., additional, Spinzi, G., additional, Russo, F.P., additional, Chemello, L., additional, Vincenzi, V., additional, Grossi, P., additional, Buscarini, E., additional, Cardaci, G., additional, Soria, A., additional, Menzaghi, B., additional, Mendeni, M., additional, Soffredini, R., additional, Colpani, M., additional, Zaltron, S., additional, Gori, A., additional, Del Poggio, P., additional, Giorgini, A., additional, Cologni, G., additional, Cartabellotta, F., additional, Di Lorenzo, F., additional, Cacciola, I., additional, Albanese, A., additional, Di Rosolini, M.A., additional, Digiacomo, A., additional, Capretti, A., additional, Memoli, M., additional, Rossi, C., additional, Cavalletto, L., additional, Capra, F., additional, Colombo, A.E., additional, Dibenedetto, C., additional, Magni, C.F., additional, Noventa, F., additional, Lampertico, P., additional, Castelli, F., additional, Alberti, A., additional, and Fagiuoli, S., additional

Published
2019
Full Text
View/download PDF

17. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

Author

Cabibbo, G., primary, Celsa, C., additional, Calvaruso, V., additional, Petta, S., additional, Cacciola, I., additional, Cannavò, M.R., additional, Madonia, S., additional, Rossi, M., additional, Magro, B., additional, Rini, F., additional, Distefano, M., additional, Larocca, L., additional, Prestileo, T., additional, Malizia, G., additional, Bertino, G., additional, Benanti, F., additional, Licata, A., additional, Scalisi, I., additional, Mazzola, G., additional, Di Rosolini, M.A., additional, Alaimo, G., additional, Averna, A., additional, Cartabellotta, F., additional, Alessi, N., additional, Guastella, S., additional, Russello, M., additional, Scifo, G., additional, Squadrito, G., additional, Raimondo, G., additional, Craxì, A., additional, Di Marco, V., additional, and Cammà, C., additional

Published
2019
Full Text
View/download PDF

19. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

Author

Calvaruso, Vincenza, primary, Cabibbo, Giuseppe, additional, Cacciola, Irene, additional, Petta, Salvatore, additional, Madonia, Salvatore, additional, Bellia, Alessandro, additional, Tinè, Fabio, additional, Distefano, Marco, additional, Licata, Anna, additional, Giannitrapani, Lydia, additional, Prestileo, Tullio, additional, Mazzola, Giovanni, additional, Di Rosolini, Maria Antonietta, additional, Larocca, Licia, additional, Bertino, Gaetano, additional, Digiacomo, Antonio, additional, Benanti, Francesco, additional, Guarneri, Luigi, additional, Averna, Alfonso, additional, Iacobello, Carmelo, additional, Magro, Antonio, additional, Scalisi, Ignazio, additional, Cartabellotta, Fabio, additional, Savalli, Francesca, additional, Barbara, Marco, additional, Davì, Antonio, additional, Russello, Maurizio, additional, Scifo, Gaetano, additional, Squadrito, Giovanni, additional, Cammà, Calogero, additional, Raimondo, Giovanni, additional, Craxì, Antonio, additional, Di Marco, Vito, additional, Craxì, A., additional, Di Marco, V., additional, Cammà, C., additional, Calvaruso, V., additional, Petta, S., additional, Cabbibbo, G., additional, Colletti, P., additional, Mazzola, G., additional, Cascio, A., additional, Montalto, G., additional, Licata, A., additional, Giannitrapani, L., additional, Prestileo, T., additional, Di Lorenzo, F., additional, Sanfilippo, A., additional, Ficalora, A., additional, Madonia, S., additional, Tinè, F., additional, Malizia, G., additional, Latteri, F., additional, Maida, M., additional, Cartabellotta, F., additional, Vassallo, R., additional, Cacciola, I., additional, Caccamo, G., additional, Maimone, S., additional, Saitta, C., additional, Squadrito, G., additional, Raimondo, G., additional, Mondello, L., additional, Smedile, A., additional, D’Andrea, S., additional, Bertino, G., additional, Ardiri, A.L., additional, Frazzetto, E., additional, Rigano, G., additional, Montineri, A., additional, Larocca, L.N., additional, Cacopardo, B., additional, Benanti, F., additional, Russello, M., additional, Benigno, R., additional, Bellia, A., additional, Iacobello, C., additional, Davì, A., additional, Di Rosolini, M.A., additional, Digiacomo, A., additional, Fuduli, G., additional, Scifo, G., additional, Distefano, M., additional, Portelli, V., additional, Savalli, F., additional, Scalici, I., additional, Gioia, G., additional, Magro, A., additional, Alaimo, G., additional, Alinovi, M.R., additional, Salvo, A., additional, Averna, A., additional, Lomonaco, F., additional, Guarneri, L., additional, Maffeo, F., additional, Falzone, E., additional, and Pulvirenti, F., additional

Published
2018
Full Text
View/download PDF

20. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort

Author

Calvaruso, V., primary, Petta, S., additional, Cacciola, I., additional, Cabibbo, G., additional, Cartabellotta, F., additional, Di Rosolini, A., additional, Davì, A., additional, Cannavò, M., additional, Russello, M., additional, Distefano, M., additional, Scifo, G., additional, Di Lorenzo, F., additional, Prestileo, T., additional, La Rocca, L., additional, Montineri, A., additional, Fiduli, G., additional, Digiacomo, A., additional, Cannizzaro, M., additional, Madonia, S., additional, Licata, A., additional, Malizia, G., additional, Alaimo, G., additional, Bertino, G., additional, Cacopardo, B., additional, Iacobello, C., additional, Averna, A., additional, Guarneri, L., additional, Scalisi, I., additional, Mazzola, G., additional, Mondello, L., additional, Portelli, V., additional, Squadrito, G., additional, Cammà, C., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2018
Full Text
View/download PDF

24. Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to hepatitis C virus infection: The real-life experience of the Sicily registry

Author

Cacciola, I., primary, Petta, S., additional, Distefano, M., additional, Cannavò, M.R., additional, Davì, A., additional, Madonia, S., additional, Calvaruso, V., additional, Larocca, L., additional, Di Lorenzo, F., additional, Digiacomo, A., additional, Bertino, G., additional, Licata, A., additional, Latteri, F., additional, Benanti, F., additional, Volpes, R., additional, Guarneri, L., additional, Averna, A., additional, Scalisi, I., additional, Iacobello, C., additional, Colletti, P., additional, Cartabellotta, F., additional, Portelli, V., additional, Russello, M., additional, Scifo, G., additional, Squadrito, G., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2017
Full Text
View/download PDF

25. Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs)

Author

Calvaruso, V., primary, Cabibbo, G., additional, Cacciola, I., additional, Petta, S., additional, Madonia, S., additional, Bellia, A., additional, Tinè, F., additional, Distefano, M., additional, Giannitrapani, L., additional, Prestileo, T., additional, Mazzola, G., additional, Davì, A., additional, Larocca, L., additional, Ardiri, A., additional, Digiacomo, A., additional, Gussio, M., additional, Guarneri, L., additional, Magro, A., additional, Averna, A., additional, Iacobello, C., additional, Scalisi, I., additional, Cartabellotta, F., additional, Savalli, F., additional, Russello, M., additional, Scifo, G., additional, Squadrito, G., additional, Cammà, C., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2017
Full Text
View/download PDF

26. Risk of hepatocellular carcinoma (HCC) recurrence in HCV cirrhotic patients treated with Direct Acting Antivirals (DAAs)

Author

Cabibbo, G., primary, Cacciola, I., additional, Cannavò, M.R., additional, Madonia, S., additional, Calvaruso, V., additional, Petta, S., additional, Distefano, M., additional, Larocca, L., additional, Prestileo, T., additional, Tinè, F., additional, Digiacomo, A., additional, Bertino, G., additional, Giannitrapani, L., additional, Benanti, F., additional, Davì, A., additional, Volpes, R., additional, Scalisi, I., additional, Iacobello, C., additional, Mazzola, G., additional, Cartabellotta, F., additional, Guarneri, L., additional, Portelli, V., additional, Averna, A., additional, Russello, M., additional, Scifo, G., additional, Squadrito, G., additional, Raimondo, G., additional, Craxì, A., additional, Di Marco, V., additional, and Cammà, C., additional

Published
2017
Full Text
View/download PDF

28. Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis

Author

Calvaruso, V., primary, Cacciola, I., additional, Licata, A., additional, Madonia, S., additional, Benigno, R., additional, Bronte, F., additional, Petta, S., additional, Malizia, G., additional, Bertino, G., additional, Distefano, M., additional, Volpes, R., additional, Montineri, A., additional, Digiacomo, A., additional, Alaimo, G., additional, Cacopardo, B., additional, Davì, A., additional, Guarneri, L., additional, Scalisi, I., additional, Mazzola, G., additional, Cartabellotta, F., additional, Portelli, V., additional, Russello, M., additional, Squadrito, G., additional, Raimondo, G., additional, Craxì, A., additional, Cammà, C., additional, and Di Marco, V., additional

Published
2017
Full Text
View/download PDF

29. Efficacy and safety of 12-week DAA regimens in HCV genotype 1b patients with compensated cirrhosis: data of RESIST-HCV Cohort

Author

Madonia, S., primary, Calvaruso, V., additional, Filomia, R., additional, Cannavò, M.R., additional, Di Stefano, M., additional, Russello, M., additional, Davì, A., additional, Scifo, G., additional, Volpes, R., additional, Montineri, A., additional, Ficalora, R., additional, Malizia, G., additional, Digiacomo, A., additional, Bertino, G., additional, Alaimo, G., additional, Licata, A., additional, Cacopardo, B., additional, Averna, A., additional, Guarneri, L., additional, Scalisi, I., additional, Colletti, P., additional, Cartabellotta, F., additional, Savalli, F., additional, Cannizzaro, M., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2017
Full Text
View/download PDF

30. Occurrence of hepatocellular carcinoma in patients with hepatitis C virus related liver disease treated with direct-acting antivirals

Author

Calvaruso, V., primary, Cabibbo, G., additional, Cacciola, I., additional, Petta, S., additional, Madonia, S., additional, Bellia, A., additional, Stefano, M.D., additional, Giannitrapani, L., additional, Tinè, F., additional, Magro, A., additional, Davì, A., additional, Larocca, L., additional, Ardiri, A., additional, Digiacomo, A., additional, Gussio, M., additional, Guarneri, L., additional, Scalisi, I., additional, Mazzola, G., additional, Cartabellotta, F., additional, Savalli, F., additional, Russello, M., additional, Scifo, G., additional, Squadrito, G., additional, Cammà, C., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2017
Full Text
View/download PDF

31. Efficacy of oral Direct Acting Antivirals for the treatment of chronic hepatitis/cirhhosis due to hepatitis C virus infection: the real-life experience of the Sicily Registry

Author

Cacciola, I., primary, Petta, S., additional, Di Stefano, M., additional, Cannavò, M.R., additional, Davì, A., additional, Madonia, S., additional, Calvaruso, V., additional, Rocca, L.L., additional, Di Lorenzo, F., additional, Digiacomo, A., additional, Bertino, G., additional, Licata, A., additional, Benanti, F., additional, Volpes, R., additional, Guarneri, L., additional, Averna, A., additional, Scalisi, I., additional, Iacobello, C., additional, Colletti, P., additional, Cartabellotta, F., additional, Portelli, V., additional, Russello, M., additional, Scifo, G., additional, Squadrito, G., additional, Raimondo, G., additional, Craxì, A., additional, and Di Marco, V., additional

Published
2017
Full Text
View/download PDF

32. Risk of hepatocellular carcinoma recurrence in hepatitis C cirrhotic patients treated with direct acting antivirals

Author

Cabibbo, G., primary, Cacciola, I., additional, Cannavò, M.R., additional, Madonia, S., additional, Calvaruso, V., additional, Petta, S., additional, Di Stefano, M., additional, Larocca, L., additional, Prestileo, T., additional, Tinè, F., additional, Digiacomo, A., additional, Bertino, G., additional, Giannitrapani, L., additional, Benanti, F., additional, Davì, A., additional, Volpes, R., additional, Guarneri, L., additional, Averna, A., additional, Scalisi, I., additional, Iacobello, C., additional, Mazzola, G., additional, Cartabellotta, F., additional, Portelli, V., additional, Russello, M., additional, Scifo, G., additional, Squadrito, G., additional, Raimondo, G., additional, Craxì, A., additional, Di Marco, V., additional, and Cammà, C., additional

Published
2017
Full Text
View/download PDF

33. Treatment of elderly HCV patients with severe fibrosis: safety and efficacy data from RESIST-HCV, a large regional database

Author

Di Marco, V., primary, Squadrito, G., additional, Davì, A., additional, Scifo, G., additional, Russello, M., additional, Volpes, R., additional, Montineri, A., additional, Madonia, S., additional, Prestileo, T., additional, Digiacomo, A., additional, Tripodi, N., additional, Bertino, G., additional, Tinè, F., additional, Licata, A., additional, Magro, A., additional, Cacopardo, B., additional, Salvo, A., additional, Mannino, G., additional, Scalisi, I., additional, Colletti, P., additional, Guarneri, L., additional, Portelli, V., additional, Cartabellotta, F., additional, Raimondo, G., additional, and Craxì, A., additional

Published
2016
Full Text
View/download PDF

36. The HCV Sicily Network: a web-based model for the management of HCV chronic liver diseases.

Author

CARTABELLOTTA, F. and DI MARCO, V.

Abstract

OBJECTIVE: Epidemiological studies report that in Sicily reside about 30,000 citizens with a diagnosis of chronic hepatitis due to HCV. The availability of direct antiviral action (DAA) is a real therapeutic breakthrough, but the high cost of the therapeutic regimes limits their use and forced the National Health System to establish clinical priority for the treatment. MATERIALS AND METHODS: The HCV Sicily Network is a web-based model of best medical practice, which was designed to improve the management and the treatment of HCV chronic hepatitis and cirrhosis. The network includes 41 centers and 84 gastroenterologists or infectivologists connected by a web platform that recorder the diagnosis and the clinic priority for the therapy. RESULTS: From March 2015 to September 2016, 9,965 patients (57% male, mean age 61 years, 34% with age over 70 years) have been recorded in the web platform, 3,319 patients completed the treatment, and 1,754 completed the 12 weeks of follow- up. The Sustained Virological Response (SVR) was achieved in 1,541 patients (87.8%), while 136 patients (7.7%) 77 patients (4.5%) experienced a virological relapse during the 12 weeks of follow-up. CONCLUSIONS: The HCV Sicily Network is an excellent system for the Regional Department of Health that can have a real estimation of patients that received an efficacy, but high-cost therapy. [ABSTRACT FROM AUTHOR]

Published
2016

38. The HCV Sicily Network: A web-based model for the management of HCV chronic liver diseases

Author

Cartabellotta, F., Di Marco, V., Craxì, A., Almasio, P., Cammà, C., Calvaruso, V., Petta, S., Colletti, P., Mazzola, G., Montalto, G., Licata, A., Giannitrapani, L., Prestileo, T., Di Lorenzo, F., Dalle Nogare, R., Sanfilippo, A., Ficalora, A., Madonia, S., Tinè, F., Malizia, G., Vassallo, R., Volpes, R., Cacciola, I., Caccamo, G., SERGIO MAIMONE, Saitta, C., Squadrito, G., Raimondo, G., Tripodi, N., D Andrea, S., Bertino, G., Ardiri, A. L., Proiti, M., Frazzetto, E., Rigano, G., Montineri, A., Larocca, L. N., Iacobello, C., Cacopardo, B., Benanti, F., Russello, M., Benigno, R., Mannino, G., Davì, A., Di Rosolini, M. A., Digiacomo, A., Fuduli, G., Scifo, G., Di Stefano, M., Portelli, V., Savalli, F., Geraci, C., Scalici, I., Gioia, G., Magro, A., Alaimo, G., Salvo, A., Averna, A., Lomonaco, F., Quattrocchi, U., Guarneri, L., Maffeo, F., Falzone, E., Pulvirenti, F., Cartabellotta, F., and Di Marco, V.

Subjects
Antiviral Agent, Male, Internet, Hepaciviru, Hepatitis C virus, Interferon-alpha, Direct antiviral agent drugs (DAA), Web-based network, Pharmacology (medical), Hepacivirus, Hepatitis C, Chronic, Middle Aged, Direct antiviral agent drugs (DAA, Antiviral Agents, Community Networks, Treatment Outcome, Drug Therapy, Combination, Humans, Ribavirin, Sicily, Human
Abstract

Epidemiological studies report that in Sicily reside about 30,000 citizens with a diagnosis of chronic hepatitis due to HCV. The availability of direct antiviral action (DAA) is a real therapeutic breakthrough, but the high cost of the therapeutic regimes limits their use and forced the National Health System to establish clinical priority for the treatment.The HCV Sicily Network is a web-based model of best medical practice, which was designed to improve the management and the treatment of HCV chronic hepatitis and cirrhosis. The network includes 41 centers and 84 gastroenterologists or infectivologists connected by a web platform that recorder the diagnosis and the clinic priority for the therapy.From March 2015 to September 2016, 9,965 patients (57% male, mean age 61 years, 34% with age over 70 years) have been recorded in the web platform, 3,319 patients completed the treatment, and 1,754 completed the 12 weeks of follow-up. The Sustained Virological Response (SVR) was achieved in 1,541 patients (87.8%), while 136 patients (7.7%) 77 patients (4.5%) experienced a virological relapse during the 12 weeks of follow-up.The HCV Sicily Network is an excellent system for the Regional Department of Health that can have a real estimation of patients that received an efficacy, but high-cost therapy.

40. Real life experiences in HCV management in 2018

Author

Nicola Caporaso, Giovanni Battista Gaeta, Stefano Bonora, Giovanni Di Perri, Francesca Ceccherini-Silberstein, Sergio Babudieri, Raffaele Bruno, Giuliano Rizzardini, Pietro Lampertico, Pietro Andreone, Gloria Taliani, Alessio Aghemo, Tullio Prestileo, Nicola Coppola, Anna Linda Zignego, Antonio Gasbarrini, Vito Di Marco, Massimo Andreoni, F. Cartabellotta, Adriano M. Pellicelli, Alfredo Alberti, Giovanni Raimondo, Maurizia Rossana Brunetto, Valeria Cento, Alessia Ciancio, Mauro Viganò, Savino Bruno, Massimo Puoti, Carlo Federico Perno, Vincenza Calvaruso, Antonio Craxì, Piero Colombatto, Stefano Fagiuoli, Mauro Viganò, Massimo Andreoni, Carlo Federico Perno, Antonio Craxì, Alessio Aghemo, Alfredo Alberti, Pietro Andreone, Sergio Babudieri, Stefano Bonora, Maurizia Rossana Brunetto ORCID Icon, Raffaele Bruno, Savino Bruno, Vincenza Calvaruso, Nicola Caporaso, Fabio Cartabellotta, Francesca Ceccherini-Silberstein, Valeria Cento, Alessia Ciancio, Piero Colombatto ORCID Icon, Nicola Coppola, Vito Di Marco, Giovanni Di Perri, Stefano Fagiuoli, Giovanni Battista Gaeta, Antonio Gasbarrini ORCID Icon, Pietro Lampertico, Adriano Pellicelli, Tullio Prestileo, Massimo Puoti, Giovanni Raimondo, Giuliano Rizzardini, Gloria Taliani & Anna Linda Zignego (for the AdHoc (Advancing Hepatitis C for the Optimization of Cure) Working Party.) ORCID Icon, Vigano M., Andreoni M., Perno C.F., Craxi A., Aghemo A., Alberti A., Andreone P., Babudieri S., Bonora S., Brunetto M.R., Bruno R., Bruno S., Calvaruso V., Caporaso N., Cartabellotta F., Ceccherini-Silberstein F., Cento V., Ciancio A., Colombatto P., Coppola N., Di Marco V., Di Perri G., Fagiuoli S., Gaeta G.B., Gasbarrini A., Lampertico P., Pellicelli A., Prestileo T., Puoti M., Raimondo G., Rizzardini G., Taliani G., Zignego A.L., Viganò, Mauro, Andreoni, Massimo, Perno, Carlo Federico, Craxì, Antonio, Aghemo, Alessio, Alberti, Alfredo, Andreone, Pietro, Babudieri, Sergio, Bonora, Stefano, Brunetto, Maurizia Rossana, Bruno, Raffaele, Bruno, Savino, Calvaruso, Vincenza, Caporaso, Nicola, Cartabellotta, Fabio, Ceccherini-Silberstein, Francesca, Cento, Valeria, Ciancio, Alessia, Colombatto, Piero, Coppola, Nicola, Di Marco, Vito, Di Perri, Giovanni, Fagiuoli, Stefano, Gaeta, Giovanni Battista, Gasbarrini, Antonio, Lampertico, Pietro, Pellicelli, Adriano, Prestileo, Tullio, Puoti, Massimo, Raimondo, Giovanni, Rizzardini, Giuliano, Taliani, Gloria, Zignego, Anna Linda, Vigano, M., Andreoni, M., Perno, C. F., Craxi, A., Aghemo, A., Alberti, A., Andreone, P., Babudieri, S., Bonora, S., Brunetto, M. R., Bruno, R., Bruno, S., Calvaruso, V., Caporaso, N., Cartabellotta, F., Ceccherini-Silberstein, F., Cento, V., Ciancio, A., Colombatto, P., Coppola, N., Di Marco, V., Di Perri, G., Fagiuoli, S., Gaeta, G. B., Gasbarrini, A., Lampertico, P., Pellicelli, A., Prestileo, T., Puoti, M., Raimondo, G., Rizzardini, G., Taliani, G., Zignego, A. L., Vigano, M, Andreoni, M, Perno, C, Craxi, A, Aghemo, A, Alberti, A, Andreone, P, Babudieri, S, Bonora, S, Brunetto, M, Bruno, R, Bruno, S, Calvaruso, V, Caporaso, N, Cartabellotta, F, Ceccherini-Silberstein, F, Cento, V, Ciancio, A, Colombatto, P, Coppola, N, Di Marco, V, Di Perri, G, Fagiuoli, S, Gaeta, G, Gasbarrini, A, Lampertico, P, Pellicelli, A, Prestileo, T, Puoti, M, Raimondo, G, Rizzardini, G, Taliani, G, and Zignego, A

Subjects
0301 basic medicine, hepatitis C virus, Sofosbuvir, Sustained Virologic Response, Antiviral therapy, chronic liver disease, DAAs, HCV, Microbiology, Microbiology (medical), Infectious Diseases, Virology, medicine.disease_cause, Chronic liver disease, Health Services Accessibility, 0302 clinical medicine, direct acting antivirals, hepatitis C viru, Mass Screening, 030212 general & internal medicine, Chronic, ComputingMilieux_MISCELLANEOUS, Hepatitis C, Hepatitis B, Pibrentasvir, Antiviral Agents, Disease Progression, Hepatitis C, Chronic, Humans, Italy, medicine.drug, Human, Settore MED/17 - Malattie Infettive, Hepatitis C virus, 030106 microbiology, Infectious Disease, 03 medical and health sciences, medicine, Mass screening, DAA, Hepatitis B virus, Antiviral Agent, business.industry, medicine.disease, business
Abstract

Introduction: Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Treatment of chronic hepatitis C has considerably improved in the last few years thanks to the introduction of direct-acting antivirals able to achieve sustained virological response in more than 95% of patients. Successful anti-HCV treatment can halt liver disease progression and solve the HCV-related extra-hepatic manifestations, eventually reducing liver-related and overall mortality. Areas covered: With the aim to respond to unmet needs in patient’s identification, universal access to antiviral therapy and treatment optimization in specific setting of HCV-infected patients, a group of Italian experts met in Stresa in May 2018. The summary of the considerations arising from this meeting and the final statements are reported in this paper. Expert commentary: All the advances on HCV cure may have a real clinical impact not only in individual patients but also at the social health level if they are applied to all infected patients, independently from the stage of liver disease. Further improvements are needed in order to attain HCV elimination, such as the development of an enhanced screening program working in parallel to the present treatment options.

Published
2018

41. Management of Patients with Gastric or Gastroesophageal Junction Cancer: From Theory to Integrated Clinical Path- ways Implementation in the Real World

Author

R, Guggino, N, Borsellino, M, Spada, F, Verderame, P, Mezzatesta, P, Marchesa, A, Firenze, F, Cartabellotta, I, Fazio, S, Pergolizzi, C, Callari, V, Gebbia, Guggino, R, Borsellino, N, Spada, M, Verderame, F, Mezzatesta, P, Marchesa, P, Firenze, A, Cartabellotta, F, Fazio, I, Pergolizzi, S, Callari, C, and Gebbia, V

Subjects
flowchart, Italy, esophagogastric junction cancer, Stomach Neoplasms, gastric cancer, Critical Pathways, Humans, clinical pathway, Esophagogastric Junction, Prospective Studies, multidisciplinary team
Abstract

Introduction: Best care of esophagogastric junction and gastric cancer (EGC) requires a complex, timely interaction between members of a multi-disciplinary team (MDT). An integrated clinical pathway (ICP) is necessary to achieve this goal as well as the implementation of its use in daily practice. The objective of this study was to elaborate on an integrated clinical pathway for the multi-disciplinary management of ECG. Authors also put in act an implementation program to improve adherence to guidelines thought an ICP. Method: This prospective work carried out by a multi-institutional MDT in Italy identified expert panel extracted relevant recommendations and/or statements from published papers and guidelines obtaining a set of crucial interventions employed the Estimate-Talk-Estimate method. A flow-chart diagram was elaborated to elicit the process at a glance. The primary outcome measure was the elaboration of an ICP with a high consensus rate also reported as a snapshot diagram and its implementation in daily clinical practice. An accredited certification body agency validated results, and an implementation process was started in several hospitals known to treat ECG. Results: A methodologist aggregated a multi-disciplinary panel of experts from different institutions. The panel elaborated a flow-chart diagram with crucial intervention highlight and connecting lines, as well as outcome measures. An accredited certification body agency validated the entire process, representing the basis for empowerment and implementation among patients and oncological professionals in various hospitals. Conclusion: The multi-disciplinary and multi-institutional expert panel successfully elaborated on a validated ICP for all stages ECG. An in-hospital implementation program has been programmed.

Published
2022

42. Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort

Author

Salvatore Petta, Antonio Craxì, Giuseppe Malizia, Gaetano Bertino, Giuseppe Cabibbo, Salvatore Battaglia, G. Scifo, Irene Cacciola, Maurizio Russello, Giovanni Squadrito, F. Cartabellotta, Giovanni Raimondo, F. Benanti, Tullio Prestileo, A. Montineri, Vincenza Calvaruso, Calogero Cammà, Salvatore Madonia, Maria Antonietta Di Rosolini, A. Digiacomo, Marco Enea, Marco Distefano, Anna Licata, Vito Di Marco, Calvaruso V., Petta S., Cacciola I., Cabibbo G., Cartabellotta F., Distefano M., Scifo G., Di Rosolini M.A., Russello M., Prestileo T., Madonia S., Malizia G., Montineri A., Digiacomo A., Licata A., Benanti F., Bertino G., Enea M., Battaglia S., Squadrito G., Raimondo G., Cammà Calogero., Craxi A., and Di Marco V.

Subjects
Male, medicine.medical_specialty, Cirrhosis, Hepatitis C virus, Chronic Hepatitis, Competing risks, Survival, Hepacivirus, medicine.disease_cause, Chronic liver disease, competing risk, Antiviral Agents, Gastroenterology, survival, chronic hepatiti, Virology, Diabetes mellitus, Internal medicine, medicine, Humans, chronic hepatitis, cirrhosis, competing risks, survival, Aged, competing risks, Hepatology, business.industry, cirrhosis, Hazard ratio, Albumin, Original Articles, Hepatitis C, Chronic, Middle Aged, medicine.disease, Hepatitis C, digestive system diseases, Infectious Diseases, Cardiovascular Diseases, Cohort, Original Article, Female, chronic hepatitis, business, Kidney disease, cirrhosi
Abstract

Real-world evidence on the course of Hepatitis C Virus (HCV) chronic liver disease after Sustained Virologic Response (SVR) obtained with direct-acting antiviral drugs (DAAs) are still limited, and the effects on mortality remain unclear. We evaluated the post-treatment survival of 4307 patients in the RESIST-HCV cohort (mean age 66.3±11.6years, 56.9% males, 24.7% chronic hepatitis, 66.9% Child-Pugh A cirrhosis and 8.4% Child-Pugh B cirrhosis) treated with DAAs between March 2015 and December 2016 and followed for a median of 73weeks (range 16–152). Proportional cause-specific hazard regression for competing risks was used to evaluate the survival and to assess the predictors of liver and cardiovascular death. Overall, 94.7% of patients achieved SVR while 5.3% were HCV RNA-positive at last follow-up. Sixty-three patients (1.4%) died during the observation period. SVR was associated with a decreased risk of liver mortality (hazard ratio,HR0.09, beta −2.37, p&nbsp

Published
2021

43. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

Author

A. Averna, Rete Sicilia Selezione Terapia – Hcv, Giovanni Raimondo, F. Cartabellotta, Salvatore Guastella, Giuseppe Alaimo, Vito Di Marco, Bianca Magro, Giovanni Mazzola, L. Larocca, M.R. Cannavò, Anna Licata, Gaetano Bertino, Salvatore Madonia, Irene Cacciola, Marco Distefano, Giuseppe Cabibbo, G. Scifo, N. Alessi, Giovanni Squadrito, Antonio Craxì, Franco Trevisani, Salvatore Petta, Margherita Rossi, Maurizio Russello, Francesca Rini, Calogero Cammà, Maria Antonietta Di Rosolini, Ciro Celsa, Giuseppe Malizia, Tullio Prestileo, Vincenza Calvaruso, I. Scalisi, F. Benanti, Cabibbo G., Celsa C., Calvaruso V., Petta S., Cacciola I., Cannavo M.R., Madonia S., Rossi M., Magro B., Rini F., Distefano M., Larocca L., Prestileo T., Malizia G., Bertino G., Benanti F., Licata A., Scalisi I., Mazzola G., Di Rosolini M.A., Alaimo G., Averna A., Cartabellotta F., Alessi N., Guastella S., Russello M., Scifo G., Squadrito G., Raimondo G., Trevisani F., Craxi A., Di Marco V., Camma C., and Cammà Calogero.

Subjects
Male, 0301 basic medicine, medicine.medical_specialty, Survival rate, Carcinoma, Hepatocellular, Cirrhosis, Sustained Virologic Response, Prognosi, Hepatitis C virus (HCV), Hepatocellular carcinoma (HCC), Direct-acting antiviral (DAA), Overall survival, Prognosis, Survival rate, Liver cirrhosis, Hepacivirus, Antiviral Agents, Gastroenterology, Liver cirrhosi, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Early Hepatocellular Carcinoma, Overall survival, Prospective Studies, Hepatocellular carcinoma (HCC), Propensity Score, Aged, Aged, 80 and over, Hepatology, business.industry, Liver Neoplasms, Hazard ratio, Direct-acting antiviral (DAA), Hepatitis C, Hepatitis C virus (HCV), Middle Aged, medicine.disease, Prognosis, Liver cirrhosis, 030104 developmental biology, Hepatocellular carcinoma, Female, 030211 gastroenterology & hepatology, Neoplasm Recurrence, Local, Liver cancer, business, Viral hepatitis, Follow-Up Studies
Abstract

Background & Aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV), following successful treatment of early hepatocellular carcinoma (HCC), has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation. Methods: We prospectively enrolled 163 consecutive patients with HCV-related cirrhosis and a first diagnosis of early Barcelona Clinic Liver Cancer stage 0/A HCC, who had achieved a complete radiologic response after curative resection or ablation and were subsequently treated with DAAs. DAA-untreated patients from the ITA.LI.CA. cohort (n = 328) served as controls. After propensity score matching, outcomes of 102 DAA-treated (DAA group) and 102 DAA-untreated patients (No DAA group) were compared. Results: In the DAA group, 7/102 patients (6.9%) died, HCC recurred in 28/102 patients (27.5%) and hepatic decompensation occurred in 6/102 patients (5.9%), after a mean follow-up of 21.4 months. OS was significantly higher in the DAA group compared to the No DAA group (hazard ratio [HR] 0.39; 95% CI 0.17–0.91; p = 0.03). HCC recurrence was not significantly different between the DAA and No DAA groups (HR 0.70; 95% CI 0.44–1.13; p = 0.15). A significant reduction in the rate of hepatic decompensation was observed in the DAA group compared with the No DAA group (HR 0.32; 95% CI 0.13–0.84; p = 0.02). In the DAA group, sustained virologic response was a significant predictor of OS (HR 0.02; 95% CI 0.00–0.19; p

Published
2019

44. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients

Author

G. Cabibbo, C. Celsa, V. Calvaruso, S. Petta, I. Cacciola, M.R. Cannavò, S. Madonia, M. Rossi, B. Magro, F. Rini, M. Distefano, L. Larocca, T. Prestileo, G. Malizia, G. Bertino, F. Benanti, A. Licata, I. Scalisi, G. Mazzola, M.A. Di Rosolini, G. Alaimo, A. Averna, F. Cartabellotta, N. Alessi, S. Guastella, M. Russello, G. Scifo, G. Squadrito, G. Raimondo, A. Craxì, V. Di Marco, C. Cammà, Cabibbo, G., Celsa, C., Calvaruso, V., Petta, S., Cacciola, I., Cannavò, M.R., Madonia, S., Rossi, M., Magro, B., Rini, F., Distefano, M., Larocca, L., Prestileo, T., Malizia, G., Bertino, G., Benanti, F., Licata, A., Scalisi, I., Mazzola, G., Di Rosolini, M.A., Alaimo, G., Averna, A., Cartabellotta, F., Alessi, N., Guastella, S., Russello, M., Scifo, G., Squadrito, G., Raimondo, G., Craxì, A., Di Marco, V., and Cammà, C.

Subjects
Hepatology, Gastroenterology, DAA, Hepatocelluar carcinoma, survival, HCV cirrhosis
Abstract

Background & aims: The effectiveness of direct-acting antivirals (DAAs) against hepatitis C virus (HCV) after successful treatment of early hepatocellular carcinoma (HCC) has been studied extensively. However, the benefit in terms of overall survival (OS) remains to be conclusively demonstrated. The aim of this study was to assess the impact of DAAs on OS, HCC recurrence, and hepatic decompensation. Methods: We enrolled prospectively 163 consecutive patients with HCV-related cirrhosis and at first diagnosis of early Barcelona Clinic Liver Cancer (BCLC) 0/A HCC who had achieved a complete radiologic response after curative resection or ablation, subsequently treated with DAAs. DAA-untreated patients from ITA.LI.CA. cohort (n = 328) served as controls. After propensity-score matching, outcomes of 102 DAA-treated (DAA group) and 102 DAA-untreated patients (No DAA group) were compared. Results: In DAA group, 7/102 patients (6.9%) died, HCC recurred in 28/102 patients (27.5%) and hepatic decompensation occurred in 6/102 patients (5.9%), after a mean follow-up of 21.4 months. OS was significantly higher in DAA group compared with No DAA group (hazard ratio [HR] = 0.39; 95% confidence Interval [CI] = 0.17–0.91, p = 0.03). HCC recurrence was not significantly different between DAA and No DAA groups (HR = 0.70; 95%CI = 0.44–1.13, p = 0.15). A significant reduction in the rate of hepatic decompensation was observed in DAA group compared with No DAA group (HR = 0.32; 95%CI = 0.13-0.84, p = 0.02). In DAA group, sustained virologic response was a significant predictor of overall survival (HR 0.02, 95%CI 0.00–0.19, p < 0.001), HCC recurrence (HR 0.25, 95%CI 0.11–0.57, p < 0.001) and hepatic decompensation (HR 0.12, 95%CI 0.02-0.38, p = 0.02). Conclusions: In patients with HCV-related cirrhosis and previous successful treatment of early HCC, DAAs significantly improved OS compared with No DAA treatment.

Published
2019

45. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort

Author

Giovanni Mazzola, Antonio Craxì, Anna Licata, M. Cannizzaro, V. Portelli, Vincenza Calvaruso, Giuseppe Malizia, I. Scalisi, V. Di Marco, L. La Rocca, Salvatore Petta, A. Di Rosolini, Luigi Mondello, Giovanni Squadrito, S. Madonia, M. Russello, M. Distefano, Giuseppe Cabibbo, F. Cartabellotta, Gaetano Bertino, Carmelo Iacobello, Giuseppe Alaimo, Bruno Cacopardo, A. Averna, G. Raimondo, Calogero Cammà, M.R. Cannavò, F. Di Lorenzo, Irene Cacciola, L. Guarneri, G. Fiduli, A. Davì, Tullio Prestileo, A. Montineri, A. Digiacomo, G. Scifo, Calvaruso, V., Petta, S., Cacciola, I., Cabibbo, G., Cartabellotta, F., Di Rosolini, A., Davì, A., Cannavò, M., Russello, M., Distefano, M., Scifo, G., Di Lorenzo, F., Prestileo, T., La Rocca, L., Montineri, A., Fiduli, G., Digiacomo, A., Cannizzaro, M., Madonia, S., Licata, A., Malizia, G., Alaimo, G., Bertino, G., Cacopardo, B., Iacobello, C., Averna, A., Guarneri, L., Scalisi, I., Mazzola, G., Mondello, L., Portelli, V., Squadrito, G., Cammà, C., Raimondo, G., Craxì, A., and Di Marco, V.

Subjects
Oncology, medicine.medical_specialty, DAA, disease outcome, hepatitis C, Hepatology, business.industry, Disease outcome, Gastroenterology, 02 engineering and technology, 021001 nanoscience & nanotechnology, 03 medical and health sciences, 0302 clinical medicine, 030220 oncology & carcinogenesis, Internal medicine, Cohort, Medicine, 030211 gastroenterology & hepatology, 0210 nano-technology, business
Abstract

Background and aims: Large scale, real life data on the long term course of liver disease after HCV clearance obtained with DAAs are still scanty, and the separate effects on hepatic and non-hepatic causes of death still unclear. Method: We evaluated 4147 patients (mean age: 65.7 ± 11.5 years, 57.6% males) included in the prospective RESIST-HCV cohort who started DAAs treatment in 22 centres between March 2015 and April 2017. All patients were follow after SVR to register liver-related and unrelated outcomes. The primary endpoint was the evaluation of survival since starting DAAs. Cox regression analysis was used to assess the predictors of liver-related and unrelated death. Results: Patients were observed for a median of 50 weeks (range: 1–199), 934 (22.5%) had diagnosis of chronic hepatitis (F3 in >90%), 2851 (68.7%) had Child A cirrhosis and 362 (8.7%) had Child B cirrhosis. Overall, 3766 patients (90.8%) achieved SVR while 381 patients (9.2%) were HCV-RNA positive at the last control. Fifty-five patients (1.3%) died during the observation: 25 of them died for liver related causes and 30 for unrelated causes (16: cardiovascular disease, 6: sepsis, 8: other). The lack of SVR was associated with an increased incidence of overall mortality in comparison to patients with SVR (hazard ratio [HR]; 28.9; 95% confidence interval [CI]: 16.5–50.8; p < 0.001) and death from liver-related and unrelated causes (HR: 18.5, 95%CI: 8.2–41.3; p < 0.001 and HR: 45.5; 95%CI: 19.3–107.4; p < 0.001 respectively). By multivariate Cox regression analysis lack of SVR (HR: 14.9, 95%CI: 6.3–35.1; p < 0.001) and Child B cirrhosis (HR: 29.4, 95%CI: 3.8–223.9; p < 0.001) were independently related with liver mortality. Independent predictors of liver-unrelated mortality were no SVR (HR: 41.77, 95%CI: 17.30–100.87; p < 0.001), Child B cirrhosis (HR: 3.00, 95%CI: 1.36–6.22; p = 0.006), BMI (HR: 0.89, 95%CI: 0.81–0.98, p = 0.023) and diabetes (HR: 2.38, 95%CI: 1.13–5.00, p = 0.022). Conclusion: In this real world setting using a variety of DAA regimens SVR reduced overall mortality and risk of liver-related and unrelated deaths at all stages of disease, nut mostly in Child A cirrhosis. The effect on cardiovascular deaths, which is evident also in the pre-cirrhotic stages deserves further follow up and investigation.

Published
2018

46. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents

Author

A. Licata, Luigi Guarneri, G. Rigano, Carlo Saitta, G. Raimondo, E. Frazzetto, Giuseppe Montalto, S. Maimone, Federica Latteri, I. Scalici, G. Fuduli, A. Craxì, Giuseppe Cabibbo, Anna Licata, C. Cammà, A. Ficalora, F. Di Lorenzo, Marco Distefano, Francesca Savalli, A. Bellia, Giovanni Mazzola, Antonio Magro, Fabio Tinè, M. Distefano, Lydia Giannitrapani, M.R. Alinovi, E. Falzone, F. Tinè, F. Benanti, L.N. Larocca, F. Cartabellotta, G. Cabbibbo, V. Calvaruso, A. Digiacomo, Salvatore Petta, M.A. Di Rosolini, Giuseppe Malizia, Bruno Cacopardo, F. Lomonaco, Vincenza Calvaruso, Marcello Maida, Adriana Sanfilippo, Giuseppa Caccamo, S. Madonia, Giovanni Squadrito, G. Squadrito, Marco Barbara, M. Russello, Gaetano Bertino, L. Larocca, A. Salvo, F. Maffeo, I. Scalisi, G. Scifo, Vito Di Marco, V. Di Marco, L. Giannitrapani, Luigi Mondello, Maria Antonietta Di Rosolini, V. Portelli, A. Smedile, G. Mazzola, Giovanni Raimondo, Antonio Cascio, S. D’Andrea, Carmelo Iacobello, Maurizio Russello, F. Pulvirenti, Antonio Craxì, Calogero Cammà, Salvatore Madonia, A.L. Ardiri, R. Vassallo, R. Benigno, F. Savalli, Alessandro Bellia, T. Prestileo, A. Averna, L. Guarneri, A. Magro, A. Davì, Tullio Prestileo, C. Iacobello, P. Colletti, G. Bertino, Arturo Montineri, Antonio Davì, I. Cacciola, Irene Cacciola, G. Gioia, Giuseppe Alaimo, Calvaruso, Vincenza, Cabibbo, Giuseppe, Cacciola, Irene, Petta, Salvatore, Madonia, Salvatore, Bellia, Alessandro, Tinè, Fabio, Distefano, Marco, Licata, Anna, Giannitrapani, Lydia, Prestileo, Tullio, Mazzola, Giovanni, Di Rosolini, Maria Antonietta, Larocca, Licia, Bertino, Gaetano, Digiacomo, Antonio, Benanti, Francesco, Guarneri, Luigi, Averna, Alfonso, Iacobello, Carmelo, Magro, Antonio, Scalisi, Ignazio, Cartabellotta, Fabio, Savalli, Francesca, Barbara, Marco, Davì, Antonio, Russello, Maurizio, Scifo, Gaetano, Squadrito, Giovanni, Cammà, Calogero, Raimondo, Giovanni, Craxì, Antonio, Di Marco, Vito, Di Marco, V., Cammà, C., Calvaruso, V., Petta, S., Cabbibbo, G., Colletti, P., Mazzola, G., Cascio, A., Montalto, G., Licata, A., Giannitrapani, L., Prestileo, T., Di Lorenzo, F., Sanfilippo, A., Ficalora, A., Madonia, S., Tinè, F., Malizia, G., Latteri, F., Maida, M., Cartabellotta, F., Vassallo, R., Cacciola, I., Caccamo, G., Maimone, S., Saitta, C., Squadrito, G., Raimondo, G., Mondello, L., Smedile, A., D'Andrea, S., Bertino, G., Ardiri, A.L., Frazzetto, E., Rigano, G., Montineri, A., Larocca, L.N., Cacopardo, B., Benanti, F., Russello, M., Benigno, R., Bellia, A., Iacobello, C., Davì, A., Di Rosolini, M.A., Digiacomo, A., Fuduli, G., Scifo, G., Distefano, M., Portelli, V., Savalli, F., Scalici, I., Gioia, G., Magro, A., Alaimo, G., Alinovi, M.R., Salvo, A., Averna, A., Lomonaco, F., Guarneri, L., Maffeo, F., Falzone, E., and Pulvirenti, F.

Subjects
Liver Cirrhosis, Male, Cirrhosis, Settore MED/09 - Medicina Interna, Sustained Virologic Response, Hepacivirus, Gastroenterology, 0302 clinical medicine, RESIST-HCV, Risk Factors, Hepatocellular Carcinoma (HCC), Medicine, Liver Cancer Risk, Prospective Studies, Prospective cohort study, Settore MED/12 - Gastroenterologia, Incidence (epidemiology), Incidence, Liver Neoplasms, Hepatitis C, Middle Aged, Direct Antiviral Agents (DAAs), Sustained Virological Response (SVR), hepatitis C Virus (HCV), liver cancer risk, reduction, sofosbuvir, Italy, Liver Neoplasm, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, 030211 gastroenterology & hepatology, Female, Human, medicine.medical_specialty, Carcinoma, Hepatocellular, Liver Cirrhosi, RESIST-HCV, Liver Cancer Risk, Reduction, Sofosbuvir, Antiviral Agents, Follow-Up Studie, 03 medical and health sciences, Internal medicine, Humans, In patient, Aged, Reduction, Antiviral Agent, Hepaciviru, Hepatology, business.industry, Proportional hazards model, Risk Factor, Hepatitis C, Chronic, medicine.disease, digestive system diseases, Prospective Studie, Child-Pugh Class B, Sofosbuvir, business, Follow-Up Studies
Abstract

Background & Aims: Studies have produced conflicting results of the incidence of hepatocellular carcinoma (HCC) in patients with hepatitis C virus–associated cirrhosis treated with direct-acting antivirals (DAAs). Data from clinics are needed to accurately assess the occurrence rate of HCC in patients with cirrhosis in the real world. Methods: We collected data from a large prospective study of 2,249 consecutive patients (mean age = 65.4 years, 56.9% male) with hepatitis C virus–associated cirrhosis (90.5% with Child-Pugh class A and 9.5% with Child-Pugh class B) treated with DAAs from March 2015 through July 2016 at 22 academic and community liver centers in Sicily, Italy. HCC occurrence was evaluated by Kaplan-Meier curves. Cox regression analysis was used to identify variables associated with HCC development. Results: A sustained virologic response (SVR) was achieved by 2,140 patients (total = 95.2%; 95.9% with Child Pugh class A and 88.3% with Child Pugh class B; P

Published
2018

47. Current epidemiology of HCV in Sicily: the RESIST-HCV model

Author

F. Ceccherini-Silbertein, Walter Mazzucco, Rosanna Cusimano, Giovanni Squadrito, S. Petta, Rosalba Amodio, Bruno Cacopardo, G. Raimondo, Teresa Pollicino, Francesco Vitale, F. Cartabellotta, C. Cammà, Vincenza Calvaruso, Antonio Craxì, S Mazzola, V. Di Marco, G. Scifo, Maurizio Russello, Di Marco, V, Cartabellotta, F, Mazzucco, W, Calvaruso, V, Petta, S, Mazzola, S, Cusimano, R, Amodio, R, Scifo, G, Russello, M, Cacopardo, B, Squadrito, G, Raimondo, G, Pollicino, T, Ceccherini-Silbertein, F, Vitale, F, Camma, C, and Craxi, A

Subjects
medicine.medical_specialty, Hepatology, Resist, business.industry, Epidemiology, Gastroenterology, medicine, HCV treatment, Current (fluid), clinical surveillance, business, Intensive care medicine, epidemiology of HCV
Abstract

Background: Real-world data to guide hepatitis C virus (HCV)- related public health initiatives and linkage to care of patients are lacking in our region. Aims: To describe the epidemiological features of a large cohort of patients with chronic HCV infection from Sicily included in a regional network aimed at DAA treatment (RESIST-HCV). Methods: Demographic and clinical data were recorded on a web-based platform before starting treatment with DAAs. Gender, year of birth, HCV genotype, co-infections, stages of liver disease and co-morbidities were analyzed. Chi-square with Yates correc- tion was appliedto assess the differences between cohorts. Results: Overall, 15,270 patients were registered on the HCV- RESIST platform from March 2015 to March 2019. The analysis of demographic and viral features showed a clear-cut bimodal distribution, defining two cohorts of patients. The first (cohort 1) includes 9.939 patients (65%) born between the years 1930 and 1959, while the second (cohort 2) included 5.331 patients (35%) born between 1960 and 1999. When comparing the two cohorts, cohort 1 had a higher rate of infection with HCV Gt 1b or 2 (90% vs 47%; p

Published
2019

48. Diagnostic Accuracy of Fecal Calprotectin Assay in Distinguishing Organic Causes of Chronic Diarrhea from Irritable Bowel Syndrome: A Prospective Study in Adults and Children

Author

Giuseppe Iacono, Giuseppe Montalto, Alberto Notarbartolo, Maurizio Averna, C. Scalici, Lidia Di Prima, F. Cartabellotta, Mario Cottone, Gaetana Di Fede, Antonio Carroccio, Giovam Battista Rini, Francesca Cavataio, Carroccio, A., Iacono, G., Cottone, M., Di Prima, L., Cartabellotta, F., Cavataio, F., Scalici, C., Montalto, G., DI FEDE, G., Rini, G., Notarbartolo, A., and Averna, M.

Subjects
Adult, Diarrhea, Male, medicine.medical_specialty, Settore MED/09 - Medicina Interna, Adolescent, Clinical Biochemistry, Colonic Diseases, Functional, Inflammatory bowel disease, Gastroenterology, Coeliac disease, Diagnosis, Differential, Feces, Internal medicine, Positive predicative value, medicine, Humans, Child, Irritable bowel syndrome, Aged, business.industry, Biochemistry (medical), Child, Preschool, Chronic Disease, Female, Infant, Leukocyte L1 Antigen Complex, Middle Aged, medicine.disease, Ulcerative colitis, Food intolerance, Fece, medicine.symptom, Calprotectin, business, Human
Abstract

Background: Fecal calprotectin (FC) has been proposed as a marker of inflammatory bowel disease (IBD), but few studies have evaluated its usefulness in patients with chronic diarrhea of various causes. We evaluated the diagnostic accuracy of a FC assay in identifying “organic” causes of chronic diarrhea in consecutive adults and children.Methods: We consecutively enrolled 70 adult patients (30 males, 40 females; median age, 35 years) and 50 children (20 males, 30 females; median age, 3.5 years) with chronic diarrhea of unknown origin. All patients underwent a complete work-up to identify the causes of chronic diarrhea. FC was measured by ELISA.Results: In adult patients, FC showed 64% sensitivity and 80% specificity with 70% positive and 74% negative predictive values for organic causes. False-positive results (8 of 40 cases) were associated with the use of aspirin (3 cases) or nonsteroidal antiinflammatory drugs (1 case) and with the presence of concomitant liver cirrhosis (3 cases). False-negative results mainly included patients suffering from celiac disease (5 cases). Patients with IBD (9 cases) were identified with 100% sensitivity and 95% specificity. In pediatric patients, sensitivity was 70%, specificity was 93%, and positive and negative predictive values were 96% and 56%. False-negative results (11 of 35 cases) were associated mainly with celiac disease (6 cases) or intestinal giardiasis (2 cases).Conclusions: FC assay is an accurate marker of IBD in both children and adult patients. In adults, false negatives occur (e.g., in celiac disease) and false-positive results are seen in cirrhosis or users of nonsteroidal antiinflammatory drugs. Diagnostic accuracy is higher in children.

Published
2003

49. Long-term follow-up of hepatitis C virus-positive patients with persistently normal serum transaminases

Author

Antonino Terranova, Giuseppe Montalto, Lydia Giannitrapani, Emanuele La Spada, Elisa Campagna, F. Cartabellotta, Monica La Spada, Maurizio Soresi, La Spada, E, Soresi, M, Giannitrapani, L, La Spada, M, Campagna, E, Terranova, A, Cartabellotta, F, and Montalto, G

Subjects
Adult, Liver Cirrhosis, Male, medicine.medical_specialty, Cirrhosis, Long term follow up, Specialties of internal medicine, Normal serum, Chronic hepatitis C, Gastroenterology, Antiviral Agents, Body Mass Index, Liver disease, Interferon treatment, Internal medicine, medicine, Humans, Longitudinal Studies, Prospective Studies, Ultrasonography, Doppler, Color, Chronic hepatitis C. Persistently normal transaminases. Liver histology. Progression of disease. Interferon treatment, Proportional Hazards Models, Hepatology, medicine.diagnostic_test, business.industry, Significant difference, Histology, Alanine Transaminase, General Medicine, Hepatitis C Antibodies, Hepatitis C, Chronic, Middle Aged, medicine.disease, Surgery, Hepatitis C Virus Positive, Liver, RC581-951, Liver biopsy, Disease Progression, Elasticity Imaging Techniques, RNA, Viral, Female, Biopsy, Large-Core Needle, Persistently normal transaminases, business, Liver histology, Progression of disease
Abstract

Material and methods. This study prospectively evaluated the progression of liver disease in a group of anti-HCV-positive patients with persistently normal ALT levels (PNALT) who were HCV-RNA positive. Patients selected for this study were those who presented with PNALT according to the Italian Association for the Study of the Liver (AISF) criteria in the year 1995/96 and underwent liver biopsy. They were divided into two groups according to their ALT evolution. Forty-five patients were included in this study. Results. After a median follow-up time of 180 months twenty-five of them maintained PNALT, but two of these developed liver cirrhosis (LC) in a mean time of 174 and 202 months, respectively). Twenty patients had flares of ALT and three of them developed LC in a mean time of 162-178 months. Twelve of these patients underwent current antiviral treatment; six patients were SVR. At baseline, the 5 patients who progressed to LC had age and BMI significantly higher than patients without LC (P < 0.005 and P < 0.01, respectively). Grading (P < 0.006) and staging (P < 0.003) were also more severe at histology, while serum HDL-C levels were statistically lower (P < 0.002). Comparing patients with flares of transaminases with and without LC, we found a significant difference at baseline for age, BMI, HDL-C, grading and staging (P < 0.05; P < 0.01 and P < 0.003, respectively). Conclusion. In HCV-RNA positive patients associated with PNALT the grade of disease activity increased over the years in only half of patients and a higher degree of liver fibrosis at baseline was the major relevant factor for progression.

Catalog

Books, media, physical & digital resources
See catalog results